Latest News Archive
Please select Category, Year, and then Month to display items
03 October 2024
|
Story Ansie Barnard
|
Photo Supplied
From left to right: Londeka Mkhwanazi, Semither Mkhize, Salima van Schalkwyk, Slindokuhle Ndlovu, Asanda Mpinga, Mantombi Molefe, Ntombinkulu Khumalo, Mosebjadi Chauke and Thembinkosi Mkhwanazi.
The Amrut Foundation, in partnership with the University of the Free State (UFS), successfully hosted its Inaugural Innovathon at the UFS Qwaqwa Campus. This competition is designed to identify and support innovative products and services that not only generate profit but also contribute to the public good, with a strong emphasis on ethical business practices. Through this collaboration, students gain national exposure for their businesses and receive support to create sustainable social enterprises.
Five teams of student social entrepreneurs from the Qwaqwa campus were shortlisted to participate in the regional finals. Their selection was based on ventures that adhered to a social entrepreneurship model and demonstrated plans for long-term profitability and sustainability.
During the Innovathon, a panel of judges from the UFS, the Amrut Foundation, and the Small Enterprise Development Agency (SEDA) selected two outstanding teams to represent the UFS at the national finals, which will take place in October. The winning ventures, Biofly-Pro and Root Rescue were each awarded R20,000 to further develop and expand their initiatives.
Hemang Desai, Executive Director of the Amrut Foundation, expressed his enthusiasm for the event: "Amrut is proud to co-host the Free State leg of the inaugural Innovation Challenge with the UFS. Supporting students with entrepreneurial ambitions that align with societal care is one of our key focus areas."
Dr Grey Magaiza, Senior Lecturer and Deputy Director for the Centre for Gender and Africa Studies at the UFS, highlighted the importance of social entrepreneurship: “Social entrepreneurship is a collaborative effort towards creating sustainable and ethical business processes. The two winning projects embody these principles, and we look forward to their continued growth. In line with our Vision 130, social entrepreneurship can serve as a critical lever for university-community engagement.”
Congratulations to Biofly-Pro and Root Rescue on their well-deserved achievements!
UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08
The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.
The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.
The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.
“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.
“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.
According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.
The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.
According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.
The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.
Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004